TGFB1 and idiopathic pulmonary fibrosis: Recently, pirfenidone (an inhibitor of multiple cytokines including TGFβ, PDGF, and TNFα)12 and nintedanib (a tyrosine kinase inhibitor)13 have been shown to be effective in slowing down the decline of lung function in IPF patients.